India Life Sciences Fund Iv Domestic

Hariharnath (Hari) Buggana is the Chairman and Managing Director of InvAscent and the designated investment professional for India Life Sciences Fund IV per IFC's project documentation. He holds an MBA from J.L. Kellogg Graduate School of Management, Northwestern University, an MS in Chemical Engineering from Illinois Institute of Technology, and a BE in Chemical Engineering from University of Poona.

Nithya Govind is Managing Director at InvAscent and the SEBI-designated contact person for India Life Sciences Fund IV Domestic. She leads investment execution in the pharma and API space. She quoted on the Fleming Laboratories investment: 'with great chemistry skills and excellent operational capabilities, Fleming has established itself as one of the fastest growing API companies.' She also led the Geri Care Health Services eldercare investment.

T.P. Devarajan is a Partner at InvAscent contributing to investment execution and portfolio management for the ILSF fund family.

Anil Jagirdar is a Director at InvAscent. He led the ABI Health Technologies investment (ILSF IV), stating: 'Indian Health-Tech is always seen as a challenging space but we see this changing rapidly with increasing adoption of tech.' He holds an MBA from IIM Shillong and a BTech in Biotechnology from Osmania University.

Paritosh Nayak has 13+ years in private equity and healthcare. Prior to InvAscent, he worked at Dr. Reddy's Laboratories (6 years), Jubilant Life Sciences (2 years), and Mylan India. He holds a PGP from ISB Hyderabad and Master & Bachelor of Pharmacy from Jadavpur University.

Henal Vora previously served as VP at Tata Capital Healthcare Fund (2 investments, portfolio management), led M&A for Piramal Pharma's critical care business, and spent 5 years at KPMG investment banking. He holds an MBA from IIM Indore and BTech (CS) from IIT Kharagpur.